ANG Lifesciences India's Q1 FY 2026-27 Quarterly Results

Result Summary

• ANG Lifesciences India Ltd reported a 34.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a decline of 37.6%.
• Its expenses for the quarter were down by 15.3% QoQ and 23.5% YoY.
• The net profit increased 207.2% QoQ and increased 110.9% YoY.
• The earnings per share (EPS) of ANG Lifesciences India Ltd declined at 3.24 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

ANG Lifesciences India Ltd is a company operating in the pharmaceutical sector, primarily engaged in the manufacturing and distribution of pharmaceutical products. The company is known for its production of a wide range of pharmaceutical formulations in various therapeutic segments. As of the latest available information, no major developments or changes in the company's business operations have been reported recently. Given the nature of the pharmaceutical industry, ANG Lifesciences competes with other companies in terms of innovation, regulatory compliance, and distribution networks.

Revenue

In the first quarter of FY27, ANG Lifesciences India Ltd reported a total income of ₹15.41 crores. This represents a significant decrease of 34.9% from the previous quarter (Q4FY26), where the total income was ₹23.67 crores. Compared to the same quarter in the previous year (Q1FY26), there is a decline of 37.6%, as the total income then stood at ₹24.69 crores. These figures indicate a downward trend in revenue generation over both the sequential and annual periods.

Profitability

The company's profitability metrics for Q1FY27 highlight a challenging financial period. The Profit Before Tax (PBT) was recorded at -₹5.58 crores, marking a substantial increase in losses compared to -₹1.10 crores in Q4FY26. This is a 407.3% decline quarter-over-quarter. Similarly, when compared to Q1FY26's PBT of -₹2.73 crores, there is a drop of 104.4% year-over-year. The Profit After Tax (PAT) for Q1FY27 is -₹4.24 crores, a deterioration from -₹1.38 crores in the previous quarter and -₹2.01 crores in the same quarter of the previous year, reflecting changes of 207.2% QoQ and 110.9% YoY. The earnings per share for Q1FY27 stood at -₹3.24, compared to -₹1.07 in Q4FY26, and no value was reported for Q1FY26.

Operating Metrics

The total expenses for Q1FY27 were ₹20.99 crores, showing a reduction of 15.3% from the previous quarter's expenses of ₹24.78 crores, and a 23.5% decrease from Q1FY26's expenses of ₹27.43 crores. These reductions in expenses have not translated into profitability improvements, as the company's losses have widened. Tax-related metrics indicate a tax figure of -₹1.34 crores for Q1FY27, a significant change from the positive tax of ₹0.28 crores in Q4FY26, and a 83.6% increase from -₹0.73 crores in Q1FY26. This suggests volatility in tax liabilities or benefits across the compared periods.